Biocidium Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments, particularly in the fields of antibiotics, antifungals, oncology, and dermatology. The company has developed a broad-spectrum antibiotic platform that demonstrates over 99.99% efficacy against a significant percentage of drug-resistant bacteria, including MRSA, VRE, and CRE. Their antifungal platform has shown similar success, effectively targeting all drug-resistant fungal infections identified by the CDC and FDA. Biocidium is also advancing its oncology platform, focusing on anti-cancer drugs for various skin cancers, and is working on dermatological solutions that may allow for topical treatments of conditions that previously required more invasive oral medications.

The company boasts a robust intellectual property portfolio, emphasizing high efficacy and low toxicity in its antibiotic solutions. Among its notable projects are several novel antibiotics that have shown promise in pre-clinical trials against resistant pathogens, as well as a topical cream aimed at treating specific skin conditions. Biocidium recognizes the urgent need for new antimicrobial drugs in light of the growing threat of antibiotic resistance, particularly among vulnerable populations such as the elderly and patients undergoing complex medical treatments. Their commitment to addressing these challenges positions them as a key player in the ongoing battle against drug-resistant infections and related health complications.

United States

Biocidium’s primary focus is the development of antibiotics to treat serious multi-drug resistant (MDR) gram-positive and gram-negative bacterial infections. Biocidium maintains strong antifungal and oncology programs and continues to build positive results in areas of skin treatments including psoriasis, acne, shingles and eczema. 


Cancer

Infectious Diseases

Nervous System Diseases

Skin Diseases

Biocidium Biopharmaceuticals

Staph aureus

BCM-0184

Biologics

Melanoma

Systemic sclerosis

BCM-0644

Small Molecule Pharmaceuticals

BCM-5228

Candida albicans

BCM-0882 & BCM-0915

Enterococcus faecalis – vancomycin resistant

BCM-0146

Streptocuccus pneumoniae – MDR

BCM-0168

Carbapenem-resistant enterobacteriaceae

BCM-0242

Neisseria gonorrhoeae

BCM-0218

Acne vulgaris

BCM-0782

Pruritus

BCM-0718

California - South

California

Therapeutic

Biocidium Biopharmaceuticals

Company Details